CTOs on the Move

Affitech USA

www.affitech.com

 
Affitech USA is a Walnut Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.affitech.com
  • 1945 Arbol Grande
    Walnut Creek, CA USA 94595
  • Phone: 925.935.9803

Executives

Name Title Contact Details

Similar Companies

Progenitor Cell Therapy

Progenitor Cell Therapy, LLC, a cell therapy services company, supports the development and commercialization of cellular therapies. It offers manufacturing practices-compliant services for pre-clinical and clinical development, as well as involves in the commercialization of cellular therapies for clients in the United States and internationally.

DiaKine Therapeutics

DiaKine Therapeutics is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lg Technologies Inc

Lg Technologies Inc is a Bakersville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Summit Therapeutics

We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.

EpiVax Oncology

EpiVax Oncology is developing precision cancer immunotherapies based on mutanome-directed neo-epitopes, selected using proprietary and validated in silico predictive algorithms. Neo-epitopes are mutated and tumor specific epitopes, recognized as non-self, capable of generating highly potent specific T cell immunogenic responses against tumors, translating in improved clinical outcome. EpiVax Oncology is developing neo-epitope based therapeutic vaccines customized and specifically designed for each cancer patient, based on the genetic profiling (using next generation DNA sequencing) of each patient`s unique tumor and normal genome sequence (the mutanome). EpiVax Oncology`s ultimate purpose is to address major unmet medical needs inadequately addressed by other oncology and immuno-oncology treatments which are either only benefiting a very limited subset of patients, or prone to adverse events, or extremely costly and complex to manufacture. EpiVax Oncology`s ambition is to become a premier cancer precision medicine company, leveraging EpiVax`s world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.